Stockholm, Sweden, December 20, 2022. Egetis Therapeutics AB (publ) (Nasdaq Stockholm: EGTX) today announced a hiring Anny Bedard as president Egetis North America and as a member of the company’s management team.Mrs. Bedard has more than 25 years of international experience in established and entrepreneurial biopharmaceutical companies in a wide range of strategic and operational functions in various business environments. Her key expertise is in new market entry, strategic planning, alliance management, country and region management, product launch, sales and business development. He has 15 years of experience in the field of rare diseases. Mrs. Bedard will be responsible for establishing and maintaining a successful presence of Egetis and its products in United States and Canadaincluding the establishment of infrastructure for Egetis North Americadeveloping relationships with key national stakeholders and recruiting a highly effective team to support all initiatives required to launch successfully Emcite in 2024.Sarah Meltonformer president Egetis North Americawill leave the company to pursue other opportunities.
Nicklas WesterholmCEO of Egetis, commented: “Anny Bedard is a successful industry veteran with an outstanding track record in many areas of commercial leadership, and I am delighted to welcome her to Egetis. Over the past 15 years, she has focused on the design and implementation of market entry strategies for rare diseases and the establishment of new entities, which perfectly aligns with the goals of Egetis. Anny will be responsible for continuing to establish the commercial infrastructure for Emcitate in the US and leading our pre-launch activities ahead of Emcitate’s planned new drug filing with the FDA in 2023 and launch in 2024. We are also grateful Sarah Melton for her dedicated work to establish the presence of Egetis v North America and I wish her success in her future endeavors.
Anny Bedard, President Egetis North Americasaid: “I am delighted to join Egetis at this important strategic time for consolidation North America. I admire Egetis for his determination and courage in developing new therapeutics for rare diseases with large unmet medical needs. I am inspired by Egetis’ vision and collaborative culture and look forward to working with this team to build a strong company in North America for the benefit of patients, stakeholders and investors.“
Prior to joining Egetis, Ms. Bedard was President ABio consulting, where she devoted herself to rare diseases. Anny has advised and supported strategic decision-making for several US and EU biopharmaceutical companies across therapeutic areas, technologies and markets to drive growth at the product, franchise and enterprise levels. Before that, she was vice president, head of international business at Sarepta Therapeutics where she designed and executed Sarepta’s entry into Latin America and Asia Pacific. At Shire, she founded and led the company’s successful growth across multiple geographies and launched the company’s leading brands in Fabry, Gaucher, Hunter syndrome and hereditary angioedema. Ms. Bedard began her career at Fournier Pharma and worked at Serona US before joining Shire and Sarepta. He has a master’s degree in cell and molecular biology Laval University in Quebec, Canada.
Source
